While CRH significantly aggravated the severity of IBD (as assessed by IBD-associated body weight loss, DAI score, change in colon length, and inflammatory infiltration), 3-MA administration significantly attenuated the detrimental effects of peripheral administration of CRH on body weight loss and DAI score, but not change in colon length (Supplementary Fig. 5A–C). This evidence concerns the gene CRH and inflammatory bowel disease.